EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Two-Pronged attack on Fast-Growing lymphomas enters patient testing
Disease control Recruiting nowThis study is testing whether adding a new immunotherapy drug, epcoritamab, to a standard chemotherapy regimen (called EPOCH-R) is safe and more effective for treating aggressive B-cell lymphomas. The trial will enroll about 18 adults who have not yet received treatment for their…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Scientists test powerful new drug cocktail in fight against Fast-Growing lymphoma
Disease control Recruiting nowThis early-stage study is testing the safety of adding one or two new targeted drugs to a standard chemotherapy regimen for people with untreated, aggressive B-cell lymphoma. The goal is to see if the new combinations are safe and tolerable for patients. Researchers will enroll a…
Matched conditions: EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC